Loading...
•
Sep 30
AstraZeneca Q3 2025 Earnings Report
AstraZeneca reported strong Q3 2025 results with double-digit growth in revenue and EPS, driven by solid performance across oncology and biopharmaceuticals.
Key Takeaways
AstraZeneca delivered robust financials in Q3 2025, posting $15.19 billion in revenue and a 64% increase in operating profit. The company continued to benefit from strong demand in oncology, respiratory, and cardiovascular portfolios.
Total revenue reached $15.19 billion, up 10% at constant exchange rates.
Reported EPS rose to $1.64, with Core EPS at $2.38.
Operating income surged 64% to $3.58 billion.
Gross margin improved by 4 percentage points to 82%.
AstraZeneca
AstraZeneca
AstraZeneca Revenue by Segment
AstraZeneca Revenue by Geographic Location
Revenue by Segment
Oncology Revenue
CapyFin.comCVRM Revenue
CapyFin.comR&I Revenue
CapyFin.comRare Disease Revenue
CapyFin.comV&I Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comChina Revenue
CapyFin.comEx-China Revenue
CapyFin.comEstablished RoW Revenue
CapyFin.com Forward Guidance
Guidance for FY 2025 was reiterated with high single-digit revenue growth and low double-digit Core EPS growth expected.
Positive Outlook
- High single-digit growth expected in Total Revenue.
- Low double-digit growth expected in Core EPS.
- Core tax rate expected between 18% and 22%.
- FX impact expected to be neutral for revenue and EPS.
- Strong cash flow generation supported investment and debt reduction.
Challenges Ahead
- Biosimilar competition impacting Soliris revenue.
- Brilinta continues to decline due to generic erosion.
- Unfavorable tender order timing in some Emerging Markets.
- Operating expenses remain high due to R&D and SG&A investments.
- Global macroeconomic uncertainties remain a risk to forecasts.
Revenue & Expenses
Visualization of income flow from segment revenue to net income